Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: Review of the evidence
Charles A. Inderjeeth, Adrian C.H. Foo, Michelle M.Y. Lai and Paul Glendenning
The objective of this review was to review the published literature on the clinical efficacy and safety of specific anti osteoporosis treatments in the reduction in fracture risk in females ? 75 years of age. Two hundred and fifty-two potentially relevant abstracts were identified. Only six publications were deemed to meet full eligibility criteria and one met most criteria.
This review reinforces the irony that the least evidence is available for fragility fracture reduction in the group at greatest risk; the old old and those with non vertebral and hip fracture. Although there is good evidence for the benefit of the bisphosphonates (Alendronate and Risedronate), Teriparatide and Strontium Ranelate in vertebral fracture reduction, there are very limited data for non vertebral and hip fracture reduction. Strontium Ranelate is the only agent to date that has demonstrated a reduction in non vertebral and hip fracture events in this high risk elderly female population.
Bone, 2009, 44(5), 744-751
- Osteoporosis Drug Improves Healing After Rotator Cuff Surgery
- Efficacy of Intra-Articular Botulinum Toxin Type A in Painful Knee Osteoarthritis: A Pilot Study.
- There is inadequate evidence to determine the effectiveness of nonpharmacological and nonsurgical interventions for hand osteoarthritis: an overview of high-quality systematic reviews
- Efficacy of intra-articular hyaluronic acid in patients with osteoarthritis of the ankle: a prospective study
- Injection of Botulinum Toxin for Treatment of Chronic Lateral Epicondylitis: Systematic Review and Meta-Analysis.